From the AGA Journals

VIDEO: Meta-analysis favors anticoagulation for patients with cirrhosis and portal vein thrombosis


 

FROM GASTROENTEROLOGY

Patients with cirrhosis and portal vein thrombosis (PVT) who received anticoagulation therapy had nearly fivefold greater odds of recanalization compared with untreated patients, and were no more likely to experience major or minor bleeding, in a pooled analysis of eight studies published in the August issue of Gastroenterology (doi: 10.1053/j.gastro.2017.04.042).

Source: American Gastroenterological Association

This search yielded eight trials of 353 patients who received low-molecular-weight heparin, warfarin, or no treatment for about 6 months, with a typical follow-up period of 2 years. The reviewers found no evidence of publication bias or significant heterogeneity among the trials. Six studies evaluated complete recanalization, another set of six studies tracked progression of PVT, a third set of six studies evaluated major or minor bleeding events, and four studies evaluated spontaneous variceal bleeding. Compared with no treatment, anticoagulation was tied to a significantly greater likelihood of complete recanalization (pooled odds ratio, 3.4; 95% confidence interval, 1.5-7.4; P = .002), a significantly lower chance of PVT progressing (9% vs. 33%; pooled odds ratio, 0.14; 95% CI, 0.06-0.31; P less than .0001), no difference in bleeding rates (11% in each pooled group), and a significantly lower risk of spontaneous variceal bleeding (OR, 0.23; 95% CI, 0.06-0.94; P = .04).

“Metaregression analysis showed that duration of anticoagulation did not influence outcomes,” the reviewers wrote. “Low-molecular-weight heparin, but not warfarin, was significantly associated with a complete PVT resolution as compared to untreated patients, while both low-molecular-weight heparin and warfarin were effective in reducing PVT progression.” That finding merits careful interpretation, however, because most studies on warfarin were retrospective and lacked data on the quality of anticoagulation, they added.

“It is a challenge to treat patients with cirrhosis using anticoagulants because of the perception that the coexistent coagulopathy could promote bleeding,” the researchers wrote. Nonetheless, their analysis suggests that anticoagulation has significant benefits and does not increase bleeding risk, regardless of the severity of liver failure, they concluded.

The reviewers reported having no funding sources or conflicts of interest.

Recommended Reading

Principles learned from a successful improvement program can increase compliance and reduce hospital acquired VTEs (HA-VTEs) across multiple institutions
The Hospitalist
Preoperative VTEs occurred in 10% of cancer patients
The Hospitalist
New-onset AF boosts bad HFrEF outcomes
The Hospitalist
Guideline for reversal of antithrombotics in intracranial hemorrhage
The Hospitalist
Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis
The Hospitalist
Principles learned from a successful improvement program can increase compliance and reduce hospital acquired VTEs (HA-VTEs) across multiple institutions
The Hospitalist
Consider switch to clopidogrel for DAPT early post ACS
The Hospitalist
Infections up the risk for pregnancy-associated stroke in preeclampsia
The Hospitalist
Low-dose aspirin bests dual-antiplatelet therapy in TAVR
The Hospitalist
FDA approves betrixaban for VTE prophylaxis
The Hospitalist
   Comments ()